Vimta Labs Quarterly Results
Vimta Labs quarterly results. In Sept 2024, Vimta Labs (VIMTALABS) reported revenue ₹85 Cr and net profit ₹15 Cr — revenue +25.0% YoY. View VIMTALABS 52-week performance for the annual high/low range and current price position.
VIMTALABS Quarterly Results — Revenue, Profit & EPS Highlights
Vimta Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit VIMTALABS screener.
- Revenue of ₹85 Cr in Sept 2024 (+6.2% vs Mar 2024, +25.0% vs Sept 2023)
- Net Profit of ₹15 Cr in Sept 2024 (+25.0% vs Mar 2024, +150.0% vs Sept 2023)
- EBITDA of ₹29 Cr in Sept 2024 (+16.0% vs Mar 2024)
- Operating Margin of 33.0% in Sept 2024 (+2.0pp vs Mar 2024)
- Earnings Per Share of ₹6.88 in Sept 2024 (+23.3% vs Mar 2024)
Vimta Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VIMTALABS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 85 | 80 | 76 | 95 | 68 | 6.3% | 25.0% |
| Net Profit (₹ Cr) | 15 | 12 | 12 | 22 | 6 | - | - |
| EBITDA (₹ Cr) | 29 | 25 | 25 | 38 | 18 | - | - |
| EPS (₹) | 6.88 | 5.58 | 5.54 | 9.65 | 2.86 | - | - |
| Operating Margin (%) | 33.0% | 31.0% | 32.0% | 37.0% | 24.0% | - | - |
VIMTALABS Share Price Trend — 1-Year Movement Across Quarterly Results
Vimta Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore VIMTALABS price movement history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VIMTALABS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vimta Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores